Marshall Edwards Issued New Patent For Use Of Lead Drug Candidate ME-143 In Treating Cancer
Marshall Edwards, Inc. (Nasdaq: MSHL) announced today that the U.S. Patent and Trademark Office has issued Patent No. 8,163,795 covering the Company's lead drug candidate ME-143 for use in treating cancer. The patent is expected to provide protection until September 2025.
The Company also announced that it has received notices of allowance from the Japanese Patent Office for two patents that cover the ME-143 and ME-344 compositions of matter, respectively, and their use in treating cancer.
"This key U.S. patent for ME-143 follows on the heels of a related patent for ME-344 as well as a composition patent for both compounds, solidifying the intellectual property position surrounding our two lead oncology drug candidates," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "As we prepare for our upcoming Phase II clinical trials, we believe our strong patent estate will help to facilitate our partnering efforts both in the U.S. and in high growth markets abroad."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.